Leveraged & Inverse ChannelBiden’s Infrastructure Can Put These 2 Leveraged Funds in PlayBy Ben HernandezApril 9, 2021
Innovative ETFs ChannelGreater Regulatory Scrutiny Could Weigh on Biotech ETFsBy Max ChenMarch 24, 2021
Thematic Investing ChannelHealthcare. China. This Global X ETF Combines Two Potent SectorsBy Ben HernandezMarch 3, 2021
Innovative ETFs ChannelIllumina Earnings, Forward Guidance Strengthen Biotech ETFsBy Max ChenFebruary 12, 2021
Innovative ETFs ChannelBiotechnology ETFs Soar on Biogen’s New Alzheimer’s DrugBy Max ChenJanuary 29, 2021
Innovative ETFs ChannelConsider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021By Max ChenDecember 31, 2020
Disruptive Technology ChannelBad Ideas: The Industries on Innovation’s Chopping BlockBy Max ChenNovember 17, 2020
Innovative ETFs Channel5 Reasons Why Investors Should Consider a Healthcare ETFBy Max ChenNovember 3, 2020
Equity ETF ChannelETF Strategies to Tap into Medical Breakthroughs, Healthcare InnovationsBy Max ChenOctober 30, 2020
Innovative ETFs ChannelAn Outperforming ETF for a Post-Coronavirus Pandemic WorldBy Max ChenAugust 27, 2020
Multi-Factor ChannelHow to Gain Exposure to the Next Generation of HealthcareBy Max ChenAugust 26, 2020
Innovative ETFs ChannelBiotech ETFs Rally as ‘Operation Warp Speed’ Fuels Covid-19 ResearchBy Max ChenJuly 7, 2020
Innovative ETFs ChannelBiotech ETFs Rally After Inovio Locks in DOD Coronavirus DealBy Max ChenJune 23, 2020
